AMR

CARB-X announced Tuesday an award of up to $3.6 million (plus up to $10.2 million in milestones) to Maryland-based Novel Microdevices to develop a rapid, point-of-care, battery-powered diagnostic for sexually transmitted infections such as chlamydia and gonorrhea.

The test—which will also identify antibiotic resistance—will diagnose infections in about 25 minutes from a vaginal swab or urine sample and require no sample preparation, making it “particularly suited” for LMICs, according…

Brii Biosciences announced $155 million last week in Series C financing.

The press release said the Sino-American biotech will use the proceeds to fund clinical studies and research for its therapies for hepatitis B, Covid-19, multi-drug resistant Gram-negative bacterial infection and HIV, as well as its central nervous system disease program.

CARB-X published compulsory guidance on Monday to ensure that new antibacterial products brought to market by its funded companies are used responsibly and made available to people in LMICs.

The Stewardship and Access Plan Development Guide—created by the Boston University-led nonprofit and its partners, including the Access to Medicine Foundation, the Gates Foundation, the Global Antibiotic Research and Development Partnership, the Global Antimicrobial Resistance Innovation Fund, and…

The U.S. National Institute of Allergy and Infectious Diseases (NIAID) announced on Thursday that it has awarded a total of $2.5 million in grants to 12 institutes to support research on bacteriophage therapy as a potential strategy to combat antibacterial resistance.

In other AMR news, New York-based ContraFect announced Thursday an award from the U.S. Biomedical Advanced Research and Development Authority of $9.8 million upfront and up to $77 million in milestones to fund Phase 3…

CARB-X committed up to $3.5 million to Affinivax to support the Massachusetts-based biotech’s development of a new vaccine to prevent Staphylococcus aureus infections, according to a CARB-X press release on Tuesday.

The Boston University-led nonprofit may add up to $18.5 million to the award if the vaccine—which will use the company’s Multiple Antigen Presenting System to include a variety of staphylococcal protein antigens—reaches certain milestones.

CARB-X announced on Tuesday up to $2.2 million in funding for the University of Queensland’s octapeptin potentiator research program, which aims to develop a new drug that disables the protective cell membrane of drug-resistant Gram-negative bacteria.

Low- and middle-income countries could use engineered octapeptin peptides to “breathe new life” into old antibiotics, according to the press release.

Mentions:

The industry-backed AMR Action Fund announced new investments last week totaling more than $140 million from the Boehringer Ingelheim Foundation, the European Investment Bank and Wellcome Trust. It also appointed Henry Skinner—a venture capitalist and microbiologist who once served as a managing director of Novartis Venture Fund—as its CEO.

Skinner told STAT that the billion-dollar fund, which seeks to bring two to four new antibiotics to market by 2030, is “a bridge investment” to buy…

Evolve BioSystems announced observational study results on Tuesday showing that preterm infants fed its activated B. infantis probiotic (EVC001) had a “significantly lower level of intestinal inflammation, 62% less diaper rash, and required 62% fewer antibiotics.” Frontiers in Pediatrics published the results.

Evolve also reported last week that it has raised $55 million in Series D financing, led by food products group Cargill and investment firm Manna Tree. The California microbiome…

CARB-X announced two new investments in the first days of February.

The Boston University-led nonprofit will award up to $12.2 million to France’s Mutabilis to develop a new intravenous drug to treat infections caused by carbapenem-resistant Enterobacterales (CRE) bacteria.

CARB-X will also invest up to $17.2 million in California-based diagnostics specialist Avails Medical to fund the company’s high-speed electronic antibiotic-susceptibility testing device for blood infections…

TB Alliance announced a collaboration Monday with ZebiAI to discover, develop and deliver “better, faster-acting and affordable” tuberculosis drugs using the Massachusetts-based company’s machine learning platform.

The project joins a trend in global health: artificial intelligence-driven discoveries in recent years include potential Chagas treatments identified through a Drugs for Neglected Diseases initiative collaboration and an MIT-discovered compound that kills a broad range of…